In Vitro Renin Secretory Responses to PG₂, PGF₂α, Indomethacin and Adrenergic-Receptor Blocker Administration

Brett C. Sheppard
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses

Recommended Citation
Sheppard, Brett C., "In Vitro Renin Secretory Responses to PG₂, PGF₂α, Indomethacin and Adrenergic-Receptor Blocker Administration" (1980). Master's Theses. 3209.
https://ecommons.luc.edu/luc_theses/3209

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1980 Brett C. Sheppard
IN VITRO RENIN SECRETORY RESPONSES TO
PGE₂, PGF₂-ALPHA, INDOMETHACIN AND
ADRENERGIC-RECEPTOR BLOCKER ADMINISTRATION

by

Brett C. Sheppard

A Thesis Submitted to the Faculty of the
Graduate School of Loyola University of
Chicago, in Partial Fulfillment of the
Requirements for the Degree of
Master of Science

December
1980
ACKNOWLEDGEMENTS

I wish to thank my family for their continued support in this and all endeavors. Special appreciation is expressed to my colleague Visalakshi Rao for her friendship and willingness to help at all times. I also wish to extend my gratitude and heartfelt appreciation to Suzanne Marie Mottel for her support and understanding throughout the past two years.

Sincere gratitude and special appreciation is expressed to Dr. Genaro A. Lopez for his direction, catalytic ideas and for his friendship. I also wish to express my appreciation to Dr. John J. Peluso for giving me valuable exposure to new fields of inquiry and for his generous donation of prostaglandin E₂, F₂-alpha and indomethacin; and to Dr. Charles C. C. O'Morchoe for his comments and suggestions on the work described in this manuscript. Special acknowledgement is extended to Joanne Cygen, Kari Kendral, Michael O'Toole and Sergio Venegas for their expert technical assistance.
VITA

The author, Brett C. Sheppard, is the son of Neil N. Sheppard and Rosalyn (Constantine) Sheppard. He was born February 21, 1956, in Harvey, Illinois.

His elementary education was obtained in the public school system of Flossmoor, Illinois, and secondary education at the Homewood-Flossmoor High School, Flossmoor, Illinois, where he graduated in June, 1974.

In September of 1974 he entered the Michigan State University (East Lansing, MI). In August 1975 he transferred to the University of Wisconsin-Madison and in August, 1978, received the degree of Bachelor of Sciences with a major in Zoology.

In September of 1978, he entered the graduate program in biology at Loyola University of Chicago and was granted a graduate teaching assistantship the following year. He is currently a candidate for the degree of Master of Science in Biology. He is co-author of scientific papers published (Fed. Proc., 39: 980, 1980) or recently submitted for publication (Lopez, Hotzel, Rao, Sheppard and Romano, Eur. J.
Pharmacol., 1980; Lopez, Rao, Mottel and Sheppard, Experien-
tia, 1980), as well as co-author of papers presented at re-
gional (Illinois Acad. Sci., Lisle, IL., 1980) and national
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>i</td>
</tr>
<tr>
<td>VITA</td>
<td>ii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>iv</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>REVIEW OF RELATED LITERATURE</td>
<td>5</td>
</tr>
<tr>
<td>Introduction to the Renin-Angiotensin System</td>
<td>5</td>
</tr>
<tr>
<td>Anatomical Evidence</td>
<td>6</td>
</tr>
<tr>
<td>Regulatory Mechanisms Involved in the Control</td>
<td>6</td>
</tr>
<tr>
<td>of Renin Secretion</td>
<td>6</td>
</tr>
<tr>
<td>The Macula Densa Receptor</td>
<td>6</td>
</tr>
<tr>
<td>The Renal Baroreceptor</td>
<td>8</td>
</tr>
<tr>
<td>The Nervous System</td>
<td>9</td>
</tr>
<tr>
<td>Humoral Influences</td>
<td>21</td>
</tr>
<tr>
<td>Intrarenal Prostaglandins</td>
<td>24</td>
</tr>
<tr>
<td>MATERIALS AND METHODS</td>
<td>42</td>
</tr>
<tr>
<td>RESULTS</td>
<td>47</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>62</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1.</td>
<td>Effect of $10^{-5}$M prostaglandin $E_2$ (PGE$_2$) and $10^{-5}$M prostaglandin $F_2$-alpha (PGF$_2$-alpha) added separately, on renin release and tissue cyclic AMP content in renal cortical slices from sodium deficient rats</td>
</tr>
<tr>
<td>2.</td>
<td>Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$M prostaglandin $E_2$ (PGE$_2$) added alone or together with $10^{-4}$M propranolol (PRO) to renal cortical slices from sodium deficient rats</td>
</tr>
<tr>
<td>3.</td>
<td>Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$M prostaglandin $E_2$ (PGE$_2$) added alone or together with $10^{-4}$M phentolamine (PHEN) to renal cortical slices from sodium deficient rats</td>
</tr>
<tr>
<td>4.</td>
<td>Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$M prostaglandin $F_2$-alpha (PGF$_2$-alpha) added alone or together with $10^{-4}$M propranolol (PRO) to renal cortical slices from sodium deficient rats</td>
</tr>
<tr>
<td>5.</td>
<td>Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$M prostaglandin $F_2$-alpha (PGF$_2$-alpha) added alone or together with $10^{-4}$M phentolamine (PHEN) to renal cortical slices from sodium deficient rats</td>
</tr>
<tr>
<td>6.</td>
<td>The effect of $10^{-4}$M indomethacin (I) on resting renin release and tissue cyclic AMP content in renal cortical slices from sodium deficient rats</td>
</tr>
</tbody>
</table>
INTRODUCTION

Data generated in this laboratory (1, 2) utilizing a renal cortical slice preparation from sodium deficient rats, suggest that dopamine directly stimulates renin release via a beta-adrenoreceptor mechanism operating at the level of the juxtaglomerular cell membrane. This effect appears to be coupled with increases in the concentration of cyclic 3':5'-adenosine monophosphate (c-AMP) in the renal cortical tissue, suggesting the participation of this nucleotide as the intracellular mediator of the stimulatory effect of dopamine on renin secretion. Recently (3), we have further supported this concept by demonstrating that addition of the phosphodiesterase inhibitor, theophylline, to the kidney slice system, potentiates the renin release and c-AMP responses to exogenous dopamine administration. Additionally, we have proposed (4) that dopamine may inhibit renin release through a dopamine-specific receptor as opposed to its beta-adrenoreceptor mediated stimulatory effect, suggesting a dual regulatory role for dopamine in the overall regulation of renin release.
Intrarenal prostaglandins (PGs) have also been implicated in the control of renin release (5,6). In vivo (7,8, 213,214) and in vitro (9,10) observations suggest that exogenous prostaglandin E₂ (PGE₂) stimulates renin secretion, but in several instances (11-14) this agent was found to be ineffective in altering the release of renin. Alternatively, prostaglandin F₂-alpha (PGF₂-alpha) has been shown to either increase (10) or decrease renin release in vitro (9,13) or to have no effect in vivo (15).

Renal synthesis of prostaglandins occurs mostly in the medullary areas (16,17), but some prostaglandins can also be produced in the renal cortex (18,19). Renal cortical prostaglandin synthesis has been shown to be stimulated by arachidonic acid (C20:4) administration (20,21), and to be inhibited by the effective prostaglandin synthetase blocker, indomethacin (22,23,215), as well as by other anti-inflammatory agents (24,25). Although the mechanism by which intrarenal prostaglandins influence renin secretion may be related to their effects on the renal vasculature (26,27,216), recent in vivo data have suggested that they may affect renin release via a direct action on the juxtaglomerular cells (28).
In vitro renal cortical preparations are particularly suitable for an effective evaluation of factors which may directly influence renin secretion. The release of renin from the juxtaglomerular cells is influenced by a number of hemodynamic and humoral factors (29,30) and by the nervous system (31,32). An in vitro renal cortical system, by eliminating these influences, thus allows for the examination of a direct action of prostaglandins and other agents on renin release. Furthermore, in vivo (33,34) and in vitro (1,2,35,36,37) evidence suggests that dietary sodium deficiency not only increases resting renin release, but that it also potentiates the renin secretory rate elicited by sympathoadrenergic discharge. Recent in vitro studies (38,39,40) have additionally demonstrated that dietary sodium deficiency also potentiates the resting concentration and release of intrarenal prostaglandins. Thus, a renal cortical slice preparation from sodium deficient rats which maximizes renin release and possibly intrarenal prostaglandin concentration as well, is a viable model for investigating the mechanism of action by which intrarenal prostaglandins may influence renin release.

Therefore, in view of the conflicting nature of the data regarding renal prostaglandin mediation of renin, this study
has been designed to (1) determine if exogenously administered prostaglandins of the E and F series can directly influence renin release in a renal cortical slice system from sodium deficient rats, (2) investigate if blockade of renal alpha- and beta-adrenergic receptors modifies the renin secretory responses to prostaglandin administration, (3) examine if changes in renal cortical tissue c-AMP content in response to prostaglandin treatment are coupled with those seen in renin release, and (4) evaluate if administration of indomethacin, an effective prostaglandin synthetase inhibitor, can influence the increased resting renin secretory levels seen in sodium deficient rats. A positive finding would support the concept that intrarenal prostaglandins participate in the regulation of resting renin release in the sodium deficient state.
I. Introduction to the Renin-Angiotensin System. (RAS)

Since the discovery of renin by Tigerstedt (41) numerous studies have clearly implicated the RAS in the regulation of blood pressure, primarily via the pressor action of Angiotensin II (ANG II) on peripheral blood vessels. The ANG II octapeptide is synthesized via the catalytic action of renin. In turn, renin cleaves angiotensinogen of hepatic origin to form the decapeptide Angiotensin I (ANG I), the immediate precursor of Angiotensin II. ANG I is in turn hydrolyzed by converting enzyme, present largely in the pulmonary vascular bed, to ANG II. Subsequent proteolytic action of circulating angiotensinases results in the formation of Angiotensin III (ANG III), a peptide with little pressor activity, and inactive metabolites (30). The RAS has also been shown to function in the regulation of blood volume and electrolyte homeostasis. ANG II has been demonstrated to influence sodium excretion through its effect on the renal vasculature which alters the filtered sodium load and the sum of Starling forces acting on the peritubular capillaries (42). Additionally, ANG II infusions stimulate the synthesis and release of
aldosterone and vasopressin (43,44,217), which are of primary importance in renal sodium and water reabsorption.

II. Anatomical Evidence.

The current accepted view places the site of formation, storage and release of renin in the juxtaglomerular cells (JG) of the afferent arteriole of the mammalian kidney, although compounds with renin-like activity have been demonstrated in extrarenal regions as well (45,46). Granular cells lining the afferent arteriole wall closest to the glomerulus were first reported by Oberling and Hatt (47) and later confirmed by other investigators (48,49,218,219,220), and sodium deficiency has been shown to increase the number and granulation of rat JG cells (53,37).

III. Regulatory Mechanisms Involved in the Control of Renin Secretion.

A. The Macula Densa Receptor.

Substantial evidence suggests the existence of a functional relationship between the macula densa and the granular cells involved in renin secretion. However, the exact nature of the signal detected by the cells of the macula densa and the mechanism by which the signal is detected and transmitted to the
renin-secreting cells is still open to question. Barajas (43), based on electron micrographs of rat JG cells, has suggested that decreased contact between these cells and the macula densa cells of the distal tubule would result in increased renin secretion. This decreased stretch of the tubular cells has been attributed to a lowered sodium load in the distal tubule with an accompanying volume reduction, thus resulting in decreased contact.

Micropuncture experiments (50) point to an inverse relationship between renin release and total sodium load delivered to the macula densa. This inverse relationship has been confirmed by Nash et al. (51) who demonstrated in dogs the dissociation of renin release from renal hemodynamics and water and sodium balance, but not from the filtered load of sodium. They suggested the existence of an intrarenal, extravascular sodium-sensitive mechanism, which responds directly to changes in sodium flux across the macula densa. Recent work in the isolated rat kidney has lent support to this concept (52). However, studies utilizing retrograde injections of
high sodium buffer into the distal tubule have suggested instead a direct relationship between filtered sodium load and renin release (53,221).

3. The Renal Baroreceptor.

Embryonically, JG cells are derived from stem cells which normally form smooth muscle (54), although they have developed the ability to functionally behave as endocrine cells, which the remaining smooth muscle cells of the afferent arteriole do not have. The latter, however, can indirectly affect JG cell function by responding to changes in the stretch of their walls. Therefore, the existence of a renal vascular receptor, sensitive to stretch and thus to alterations in renal perfusion pressure has been investigated. In denervated-, adrenalectomized-, non-filtering canine kidneys, renin secretion has been observed to increase in response to decreased renal perfusion pressure associated with hemorrhage and graded suprarenal aortic constriction (55,56,57,222). This increased renin secretory response was no longer apparent when perfusion pressures were restored to normal levels. Furthermore, in vivo administration of the
smooth muscle relaxant papaverine has been demonstrated to abolish the renin secretory responses to hemorrhage in canine-denervated-, non-filtering kidneys (58), although it is possible that this effect may have been due to a direct effect of papaverine on the JG cells. Recent in vitro experiments utilizing a rat renal cortical cell suspension have shown papaverine may directly inhibit renin secretion (59).

C. The Nervous System.

1. **Central Nervous System Regulation of Renin Release.**

   The possibility of a brain renin-angiotensin system participating in the central regulation of peripheral blood pressure has long been debated. There is generalized agreement that circulating ANG II or ANG III influence some brain regions located outside the blood-brain barrier (60). Several components of the RAS have been demonstrated intracerebrally as well (51). However, the issue of whether it is renin or an isorenin which is present intracerebrally remains unresolved. Endogenous brain renin and the renin-like enzyme, Cathepsin D, co-purify by gel filtration and ammonium sulphate fractionation (62); Cathepsin D, as
does renin, will react with renin substrate to form ANG I (63), although the activity of this so-called "brain-renin" decreases above pH 7.0, while the optimal pH for renal renin activity is at 7.4 (64). Recent investigations have demonstrated a fraction of Cathepsin D which has renin-like optional activity at pH 7.4 and is effectively neutralized by anti-renin anti-sera (65,66,67, 223,224,225).

a. The Effect of Plasma Angiotensin on the Brain. Confirmation of plasma angiotensin influence on the brain was provided in an elegant experiment by Bickerton et al. (68). In this cross-perfusion study, the head of a recipient dog, isolated from its circulation but connected to its spinal cord, was perfused with blood from a donor dog receiving ANG II injected into its circulation. Peripheral arterial pressure was observed to increase in the recipient dog while ANG II was infused into the donor.

Mediation of plasma ANG II influence on the CNS must occur outside the blood-brain
barrier, since this peptide cannot cross the blood-brain barrier (69). The pressor response to ANG II infusions into the vertebral artery of dogs has been shown to occur only if the circulation to the area postrema, outside the blood-brain barrier, remains unimpaired (70). Moreover, injections of ANG II into the vertebral artery inhibit reflex vasodilation in the dog (70), suggesting a possible role for ANG II in modifying the inhibitory activity exerted by vasomotor effector neurons (70). Neural connections have also been demonstrated between the area postrema and the nucleus of the tractus solitarius (70) which receives input from the glossopharyngeal and carotid sinus nerves and in turn operate as a relay for afferent baroreceptor impulse integration (71).

Direct administration of ANG II into the cerebral ventricles causes increased secretion of both vasopressin and ACTH and a rise in blood pressure (44,72). These
responses have been mimicked by intraventricular injection of purified renin (73), and responses to both peptides are abolished by the competitive ANG II antagonist, Saralsin (73). Additionally, converting enzyme inhibitors have been shown to block the response to intracerebral injection of renin (73), thus further supporting the view that the observed responses are due to ANG II of cerebral, rather than peripheral origin.

b. Central Influence on Renal Renin Release.

The postulation that the CNS plays a role in modulating renal renin release has been arrived at as a result of the following observations: (1) Cathepsin D, an enzyme apparently containing a renin-like component, activates inactive renin in human amniotic fluid (74). This observation taken together with the intracerebral demonstration of Cathepsin D suggests a possible central physiological role for this enzyme; (2) central mediation of peripheral activation of inactive renin has been shown (75); (3) in
**vivo** pharmacological evidence indicates that stimulation of central serotoninergic pathways increases peripheral renin release (76); (4) stimulation of the posterior hypothalamus, medulla oblongata, and pons, increases renin secretion and is associated with a rise in blood pressure; and (5) renal denervation abolishes the increase in renin release in response to central stimulation (73).

Clonidine, a known central alpha-receptor agonist agent, has several actions on the brain. It decreases plasma ACTH through an action on the hypothalamus, and injections of this agent into the blood perfusing the medulla and the pons result in a significant depressor response (73). Furthermore, vertebral or carotoid arterial administration of clonidine produces a decrease in plasma renin activity (73). Bilateral lesions of the canine ventral medulla abolish the decreased splanchnic nerve discharge associated with clonidine injection, while the depressor response remains
intact. Thus, these data point to a separate site for the renin-lowering effect and the depressor responses to this agent (73).

Injections of clonidine into the cisterna magna of anesthetized, bilaterally splanchnicotomized dogs, do not result in decreased plasma renin activity, whereas the same dose injected into animals with intact splanchnic nerves result in a significant decrease in hemorrhage-stimulated increases in plasma renin activity. These data suggest that clonidine reduces sympathetically-stimulated renin via a central mechanism dependent on splanchnic nerve integrity (77). The renin-lowering effect of clonidine may be exerted through an excitatory action on intracerebral alpha-adrenoreceptors (73). Clonidine has been shown to have a greater affinity for pre- rather than post-junctional alpha-adrenoreceptors (78). However, the evidence regarding the action of clonidine on renin release is not yet complete. Clonidine appears to decrease sympathetic discharge rate
even when pre-synaptic inhibition is abolished by reserpine-induced catecholamine depletion (79). Additionally, a neurally-mediated decrease in renin secretion, which can be abolished by renal denervation, has also been reported when L-dopa is administered with carbidopa to provoke catecholamine release (80). Furthermore, while injections of norepinephrine, epinephrine and dopamine into the third ventricle of the dog increase renin secretion, injections of clonidine into the same site decrease renin secretion (73). Thus, these data indicate that agents with high affinities for post-synaptic receptors increase renin secretion while agents with high affinities for pre-synaptic receptors decrease renin secretion.

2. Peripheral Nervous System Regulation of Renin Release.

   A large body of evidence suggests that the sympathetic nervous system innervates the JG cells and thus can directly modulate renin
release. Electron microscopic studies (81-83) have clearly shown this extensive sympathetic innervation of the renin-secreting cells, and fluorescent histochemical studies and chemical assays (84,85) have further supported this view. Furthermore, circulating catecholamines of adrenal medullary origin can directly influence renin release by acting on renal adrenergic receptors, in addition to their indirect effects exerted through the renal baroreceptors and macula densa receptors (29-32).

Functional evidence for a direct sympathetic effect on renin secretion, independent of hemodynamic and macula densa influences, has been provided by numerous studies. In papaverine-treated dogs with non-filtering kidneys, electrical stimulation of the renal nerves increases renin release (86). Similarly, in vitro administration of catecholamines stimulates renin secretion (1,2,35,36,87,88, 96,98), presumably by a direct action on the JG cells.
b. The Renal Beta-Adrenergic Receptor.

Abundant in vivo and in vitro data have firmly established the concept that circulating catecholamines and norepinephrine released by renal nerve terminals, can directly stimulate renin release (1,2,89-93). This direct stimulatory effect appears to be exerted via a JG cell membrane-bound beta-adreno-receptor mechanism (36,90,94,96,100-102,104,226), since blockade of this receptor mechanism by specific pharmacological agents such as propranolol and pindolol effectively prevents the increase in renin release seen in response to sympathetic stimulation (31,36,90,92,94-97,100-104,227,228).

The stimulatory action of beta-adreno-receptor activation on renin secretion has been suggested to be coupled with a simultaneous increase in the levels of cyclic 3'5' adenosine monophosphate (c-AMP) in renal tissue (1,2,36) which may indicate that this nucleotide acts as the intracellular mediator of sympathetic stimulation of renin release.
This view has been further supported by the demonstration that the phosphodiesterase inhibitor, theophylline, potentiates the stimulatory action of catecholamines on renin release (98, 99, 105, 107). Additionally, administration of dibutyryl c-AMP to isolated rat renal cortical tissue increases renin release in a dose-dependent fashion (108), an observation which has been confirmed in other in vivo and in vitro studies (90, 106, 109).

The type of beta-adrenoreceptor specifically involved in the regulation of renin release has not yet been fully determined. Recent data suggest the involvement of a beta₁-adrenoreceptor rather than a beta₂-type similar to the one present in cardiac tissue (110-112, 230), but some in vitro studies indicate that the renal beta-adrenoreceptor may not belong to either type (113). Furthermore, Saruta et al. (114), have suggested that the decrease in renin release associated with beta-adrenergic blockade is due to a membrane stabilizing
effect of the blocking agents rather than to their functional beta-blocking actions.

c. **The Renal Alpha-Adrenergic Receptor.**

Stimulation of intrarenal alpha-adrenoceptors has been shown to result in an inhibition of renin release (100,115-117). Furthermore, alpha-adrenoreceptor antagonists have been demonstrated to abolish the inhibitory effect of alpha-adrenoreceptor activation of renin release (36,93,98,100,118). Taken together, these observations suggest an inhibitory role for intrarenal alpha-adrenoceptors in the regulation of renin release.

d. **The Renal Dopamine Receptor.**

Dopamine has been shown to be present in canine renal tissue (118). The renal vaso-dilating properties of this amine have been postulated to indirectly influence renin release (120,121,122), and these renal vascular effects apparently involve an interaction with dopamine-specific receptors located on the renal vascular walls (123,124,125).
Dopamine has also been found to increase the c-AMP content of rat renal particulate preparations (126,127) which suggest that the renal vascular actions of this amine may be mediated by adenylate cyclase systems functionally coupled with renal vascular dopaminergic receptors. Alternatively, the observed changes in renal tissue c-AMP content in response to dopamine administration may reflect an action of this agent on cells other than vascular cells, such as the JG cells, suggesting adenylate cyclase mediation of a direct effect of dopamine on renin release (128,129). This possibility has now been suggested by in vitro studies (1-3,130,131), in which dopamine administration simultaneously stimulated both renin release and tissue c-AMP content in rat renal cortical tissue. Furthermore, this effect was shown to be effectively blocked by propranolol in these studies, suggesting that mediation of the stimulatory action of dopamine on renin
secretion is via a beta-adrenoreceptor mechanism. Conversely, administration of dopamine-receptor blockers such as haloperidol (131) and d-butaclamol (4) has been demonstrated to potentiate the stimulation of renin release by dopamine, which may indicate that renal dopaminergic receptors may regulate renin release in an inhibitory fashion. The physiological significance of this dual regulation is unclear, but a similar dual type of control has been proposed to exist in regard to the action of norepinephrine on renin release (36,115,117,118).

3. Humoral Influences in the Control of Renin Release.
   a. Angiotensin II (ANG II).

   Peripheral infusions of ANG II have been shown to inhibit renin secretion (42). In sodium deficient sheep (132), chronic ANG II administration prevented the expected rise in plasma renin activity, seen in the sodium deficient state. ANG II has also been reported to inhibit renin secretion in the absence of a functional renal baroreceptor or macula densa (133), suggesting a direct inhibitory action of ANG II on the JG cells. Furthermore, Keeton
et al. (134) have suggested that infusions of saralasin, an ANG II competitive inhibitor, disrupts the ANG II short-loop, local inhibitory feedback mechanism on renin release, which is also associated with the intrarenal beta-adrenoreceptors, and in vitro observations by Ganong and Lopez (36) have demonstrated that ANG II administration inhibits the stimulatory effect of norepinephrine on renin secretion, and that this effect is coupled with corresponding decreases in the c-AMP content of the renal cortical tissue. Thus, it appears that in addition to its indirect actions in the regulation of renin release, namely, via its central and peripheral vascular effects, ANG II has the ability to locally control the secretion on renin by a direct short-loop feedback mechanism operating at the JG cell level. However, a negative feedback effect exerted by ANG II on the JG cells was not observed in a recent in vivo investigation by Baer and her associates (135).
b. Vasopressin (ADH).

Some investigators have also reported that ANG II infusions increase the plasma concentration of vasopressin (44,136,137). Since it has also been shown that vasopressin inhibits renin release (44,137,138), it may be possible that the inhibitory regulation of renin release by vasopressin may be the result of ANG II-mediated central stimulation of vasopressin release, although the actual mechanism by which vasopressin influences renin secretion remains unclear.

c. Electrolytes.

In addition to sodium, other electrolytes also appear to regulate renin secretion. Chlorine has recently been reported to increase renin release in rats independent of sodium concentration (139). In experiments with denervated, auto-transplanted canine kidneys, hypermagnesia has been demonstrated to stimulate renin release independent of hemodynamic, nervous and natriuretic factors (140). The mechanism of action involved in this effect
appears to be related to the antagonism which exists between magnesium and calcium in controlling renin release. Recent in vitro work (141) has demonstrated that potassium-free media causes a depression of renin release in renal cortical tissue, and that this effect is partially prevented when calcium is also absent from the media. Vandongen and Peart (142) have also demonstrated that ANG II will not inhibit basal renin secretion in the absence of calcium. These observations point to a regulatory influence of calcium on a JG cell membrane response to ionic influences (231,232).

4. Regulation of Renin Secretion by Intrarenal Prostaglandins.

Synthesis of prostaglandins (PG) has been demonstrated to occur in a variety of peripheral vascular beds (143,144). In the kidney, the concentration of PG synthetase is highest in the medulla and papillae but there is also significant PG production in the renal cortex (17-20,145-147). Renal cortical synthesis of prostaglandins is
dependent on the conversion of free arachidonic acid (C20:4) to the endoperoxide PGG$_2$ via the action of cyclooxygenases. Subsequent reductase activity results in the biosynthesis of PGE$_2$ or PGF$_2$-alpha while isomerases catalyze the conversion of PGG$_2$ or PGF$_2$. Additionally, PGE$_2$ may be converted to PFG$_2$-alpha via the action of PGE 9-ketoreductases (148). Although it is generally accepted that renal prostaglandins play a predominant role in the control of renal vascular dynamics (25,26,144), their presence in the renal cortex has led to numerous studies designed to investigate the possibility of a regulatory influence of these agents on renin secretion (5,6, 149-155), either directly or indirectly.

a. Indirect Regulation of Renin Secretion by Prostaglandins.

i. PG Involvement in the Macula Densa and Baroreceptor Control Mechanisms.

Prostaglandins appear to be required for effective macula densa function. In unilaterally renal denervated-, contralaterally nephrectomized-, papaverine- and
propranolol-treated anesthetized dogs, the PG synthetase inhibitor indomethacin, has been shown to abolish aortic clamp-stimulated increases in plasma renin activity (156). Additionally, indomethacin can inhibit the increased plasma renin activity associated with decreased early distal tubular sodium load in both sodium-replete and deficient rats (157).

Studies utilizing adrenalectomized-, renal denervated-, propranolol-treated, non-filtering canine kidneys with contralateral nephrectomy, have suggested a role for cortical PGs in the intrarenal baroreceptor control of renin release (158). In this study, indomethacin abolished the rise in plasma renin activity associated with decreased renal perfusion pressure and intrarenal infusion of C20:4. This suggests that cortical, rather than medullary PGs are involved in the intrarenal baroreceptor response, since medullary cyclooxygenase products cannot be
transported to the cortex via tubular fluid in treated anesthetized dogs, the PG synthetase inhibitor indomethacin, has been shown to abolish aortic clamp-stimulated increases in plasma renin activity (156). Additionally, indomethacin can inhibit the increased plasma renin activity associated with decreased early distal tubular sodium load in both sodium-replete and deficient rats (157).

Studies utilizing adrenalectomized-, renal denervated-, propranolol-treated, non-filtering canine kidneys with contralateral nephrectomy, have suggested a role for cortical PGs in the intrarenal baroreceptor control of renin release (158). In this study, indomethacin abolished the rise in plasma renin activity associated with decreased renal perfusion pressure and intrarenal infusion of C20:4. This suggests that cortical, rather than medullary PGs are involved in the intrarenal baroreceptor response, since medullary
cyclooxygenase products cannot be transported to the cortex via tubular fluid in the non-filtering kidney (158). These observations have been recently extended by the demonstration that PGE₂ and PGI₂ of cortical origin are necessary for baroreceptor stimulated renin release (159). Thus, current evidence suggests the involvement of medullary and cortical PGs in two of the three major mechanisms which regulate renin release.

ii. The Relationship Between PGs and Angiotensin II (ANG II).

In vivo evidence has indicated endogenous renal PG mediation of the ANG II short-loop feedback mechanism. Administration of the ANG I converting enzyme inhibitor, SQ 14225, results in a significant increase in plasma renin activity which is abolished following indomethacin infusion (160). Indomethacin has also been shown to decrease ANG II-induced aldosterone release in sodium deficient
rats (161). Alternatively, experiments in the isolated rat kidney suggest that ANG II increases PGE$_2$ biosynthesis (162), and the production of an increased renal venous PGE-like agent associated with low frequency renal nerve stimulation, has also been reported to be mediated by ANG II (163).

iii. PGs and the Renal Nerves.

While experimental evidence suggests a role for PGs in modulating sympathetically-evoked renin release, the mechanism involved in this action has not yet been determined (164,165). In renal-denervated dogs, treated with cyclooxygenase inhibitors while undergoing hemorrhage, plasma renin activity remained unaltered in relation to control levels (166). However, direct stimulation of the renal sympathetic nerves in anesthetized dogs has been shown to simultaneously increase renin release and PGE$_2$ levels two-fold over those of control (167). Furthermore, isoproterenol-stimulated renin release in rats is reduced by 67\% following administration of
indomethacin, while this same agent attenuated the rise in serum renin levels caused by the beta1-adrenoreceptor agonist H133/22 by 80% (168). Catecholamine infusions have also been reported to increase PG release in the isolated, perfused rabbit kidney, thus suggesting a role for the renal nerves in stimulating PG synthesis (169). These observations taken together, support the existence of a mechanism whereby sympathetic stimulation, which may be under the tonic restraint of cardiovascular reflexes, evokes simultaneous increases in renin release and PG biosynthesis, with PGs acting at a site distal to the intrarenal beta-adrenergic receptor.

iv. PG Synthetase Inhibitors and Their Relation to the RAS.

In an attempt to clarify the mechanism by which intrarenal PGs may influence renin release, the non-selective, cyclooxygenase inhibitor, indomethacin, has been utilized in a number of investigations. Indomethacin,
in doses of 5-10 mg/kg, has been reported to significantly decrease resting (basal) plasma renin activity in rabbits and dogs (19,20,233). Similar doses have also been reported to lower the level of immunoreactive renal venous PGE substances, as well as to decrease plasma renin activity in normal and hypertensive rabbits (22,24,25,170). Studies in normal and hypertensive man have generally supported these observations (171-173,234).

Indomethacin can also suppress the rise in the levels of active renin associated with furosemide administration (174) and to decrease those of inactive renin and acid-activated renin in man, which suggests that PGs may mediate the conversion of inactive to active renin (175). Additionally, recent in vivo studies have confirmed these observations and have further suggested a definite role for newly synthesized PGs in regulating renin release via a direct action on the
JG cells (19,20,177,178).

Recent in vivo investigations utilizing non-filtering-, denervated-, papaverine-treated canine kidneys, support the concept of a direct action by PGs on the JG cells to mediate renin release (28). In these studies, 60-min infusions of C20:4 (15 ug/kg/min) produced significant increases in both renin release and PG levels. On the basis of these results it appears likely that the C20:4-evoked increases in renin release are due to a prior conversion of C20:4 to prostaglandins which then influence the JG cells, independent of other regulatory mechanisms.

ii. Effect of PGE₂.

In vivo and in vitro evidence suggest that PGE₂ either increases or does not alter renin release under a variety of experimental manipulations. Utilizing a rabbit renal cortical cell preparation, PGE₂ at various concentrations (3×10⁻¹² M,
$3 \times 10^{-10}$ M, $3 \times 10^{-7}$ M) has been shown to increase renin release with maximal stimulation produced by the lowest concentration of PGE$_2$ used (9). In another study (10), a dose of 2.0 ug/ml of PGE$_2$ caused a gradual increase in renin release over sixty minutes of incubation, and PGE$_2$ doses from $3 \times 10^{-6}$ M to $3 \times 10^{-4}$ M have recently been shown to increase in vitro renin release in a dose-dependent manner in rats (179). Furthermore, in isolated rat glomeruli, administration of 5 ug/ml of C20:4 produced a tenfold increase in PGE$_2$ and a twofold increase in renin release (180). In the isolated, perfused rat kidney, thirty minute infusions of 5, 10 or 50 ng/ml of PGE$_2$ have been reported to produce significant dose-dependent increases in renin release (181). Similarly, in the anesthetized dog, 10-min. infusions of 14-60 ng/kg/min of PGE$_2$ resulted in dose-dependent increases in both renin release and renal blood flow (7), while
administration of acetylcholine, bradykinin, and the depressor agent eledoisin only increased renal blood flow without affecting renin release, thus suggesting a direct action of PGE₂ on the JG cells to influence renin release (7). Yun and his associates have also reported increases in renin release in sodium deficient dogs with non-filtering kidneys, following 60-min infusions of PGE₂ (4.12 ug/min and 1.03 ug/min), further supporting the concept of a direct role for PGs in modulating renin release (15,182). Additionally, chronic intra-renal infusion of 2 ug/min of PGE₂ over 7-8 days in unilaterally-nephrectomized, conscious dogs, resulted in eight-fold increases in plasma renin activity which was attenuated following SQ 14225 administration on day 9 (183,184). Thus, taken together, these data support the view of a direct action of PGE₂ on the renin-secreting cells to influence renin release, although the mechanism involved in this action remains unclear.
In contrast, $10^{-6}$ M PGE$_2$ has been reported to be ineffective in altering renin release in rabbit renal cortical slice preparations (13,14,185). Similarly, intrarenal infusions of PGE$_2$ (0.1-5.0 ug/min) for sixty minutes in renal-denervated, anesthetized dogs have also failed to elicit significant increases in plasma renin activity (11), and 30 min infusions of 10-5000 ng/min of PGE$_2$ have also been reported to have no effect on plasma renin activity in anesthetized dogs (12). Therefore, at present the possibility of a stimulating influence of this prostaglandin on renin secretion requires further evaluation, in view of the conflicting nature of the data currently available.

iii. Effect of PGF$_2$-alpha.

Data pertaining to a possible influence of PGF$_2$-alpha on renin secretion are also conflicting. In vitro studies using rabbit renal cortical cell preparations (9), have shown that PGF$_2$-alpha at
various doses ($3 \times 10^{-12}$ M, $3 \times 10^{-9}$ M and $3 \times 10^{-7}$ M) significantly decreases renin release. Furthermore, the addition of $10^{-12}$ M to $10^{-6}$ M of PGF$_2$-alpha to rabbit renal cortical preparations have also resulted in significant decreases in renin release in a dose-dependent fashion (13, 14). Conversely, recent studies (10), utilizing similar renal cortical systems have demonstrated that 0.2 ug/ml PGF$_2$-alpha stimulates renin release when the prostaglandin was prepared in albumin-containing physiological buffer, while the same dose inhibits basal renin release when the vehicle was ethanol (10). Alternatively, unilateral, intrarenal infusions of 1.03 ug/min of PGF$_2$-alpha for 1.5 hours had no demonstrable effect on renin release in intact canine kidneys (15).


Current evidence indicates that the PG-synthetase intermediates, the
endoperoxides, are capable of stimulating renin release \textit{in vivo} and \textit{in vitro}. For instance, \textit{in vivo} unilateral infusion of a synthetic PG-endoperoxide analogue, EPA, significantly increases renin release and this effect is prevented by prior treatment with indomethacine (186), although the rise in renin release in response to EPA administration appears to be the result of prior conversion of EPA to PGE$_2$ (186). \textit{In vitro} studies (13,14) utilizing a rabbit renal cortical preparation have also shown that the synthetic endoperoxide analogues EPA I and EPA II and the naturally occurring endoperoxide, PGG$_2$, can significantly stimulate renin release to a similar extent (60% over control levels). Since in these studies PGE$_2$ was without effect and PGF$_2$-alpha actually decreased renin secretion, it appears that the PG endoperoxides themselves are responsible for the observed rise in renin secretion.
v. **PG-elicited Stimulation of Cyclic AMP.**

It is generally accepted that intrarenal PGs stimulate renal tissue cyclic AMP levels, but whether this is a non-selective effect of PGs on intrarenal adenylate cyclase systems or a specific action on JG cell membrane adenylate cyclase complexes, is not clear. In isolated rat glomeruli, adenylate cyclase stimulation, has been shown to occur following administration of $2 \times 10^{-5} \text{M PGE}_2$, while equimolar concentrations of PGF$_2$-alpha were ineffective (187). Also, higher concentrations of PGE$_2$ and PGF$_2$-alpha ($8 \times 10^{-4} \text{M}$) have resulted in a significant stimulation of cyclic AMP content of rat renal cortical slice tissue (188). Conversely, a 10-fold decrease in the concentration of PGF$_2$-alpha resulted in the loss of the stimulatory action of this agent on renal cortical cyclic AMP content. Similar results have been reported in experiments utilizing both renal medullary and
cortical slice tissue (189,190). Unfortunately, renin release changes were not simultaneously evaluated in any of these studies. Recently, unilateral, intra-renal infusion of dibutyryl cyclic AMP into the renal artery of anesthetized dogs, has been shown to significantly stimulate renin secretion even in the presence of indomethacin, suggesting that PG-synthetase activity does not play a role in cyclic AMP-mediated renin release (191). Indomethacin has also been reported to be ineffective in altering theophylline-induced increases in plasma renin activity in rabbits (192), while theophylline has been shown to directly stimulate PG-synthetase in rabbit renal microsomes (193). Taken together, these results suggest that the stimulatory effect of PGs on renal adenylate cyclase systems may be confined to vascular and tubular cells different from the JG cells.
vi. PGs and Their Relationship to the JG Cell

Beta-adrenergic Receptor.

Independent observations that intra-renal PGs are capable of stimulating renin release as well as renal tissue cyclic AMP content, pose the attractive possibility that the effect of PGs on renin secretion may be mediated by a membrane receptor mechanism which utilizes cyclic AMP as the intracellular second messenger, similar to the beta-adrenergic receptor mechanism which modulates the stimulatory effect of catecholamines on renin release via mediation by cyclic AMP content changes (1-4,35,36). This possibility is supported by in vivo studies (194-196,235), showing that indomethacin administration can suppress the anti-hypertensive effect of beta-adrenoreceptor blockade in man, cats and rabbits. However, in isolated rat glomeruli (197), beta-adrenoreceptor blockade has failed to inhibit the increased release of renin seen in response to C20:4
infusions, thus suggesting that PGs stimulate renin release independently of a beta-adrenoreceptor mechanism. Furthermore, in vivo studies have demonstrated the failure of indomethacin to prevent the rise in plasma renin activity produced by norepinephrine and isoproterenol infusions in the dog (198). Recent studies utilizing superfused rat renal cortical slices (179), have shown that PGE$_2$-induced renin release cannot be blocked by doses of propranolol which normally abolish isoproterenol-stimulated renin release. Thus, the bulk of the evidence suggests that while cyclic AMP may perhaps mediate PG-elicited renin release, the mechanism involved in this action may not be of the beta-adrenoreceptor type and that the systems may function independently of each other in regulating renin secretion.
MATERIALS AND METHODS

Twelve male, Sprague-Dawley rats (Sprague-Dawley Co.) were fed a sodium deficient diet (Teklad Test Diet Co.) providing less than 0.02 mEq. of sodium per day for 2.5 to 3.5 weeks and had free access to distilled, deionized water. The rats were kept in a temperature- and light-controlled room (23±2°C; 12 hours light and 12 hours dark), with two animals per cage. At the end of their dietary intake period the animals were sacrificed by decapitation, their kidneys placed in Robinson's buffer medium at 4°C (199), and subsequently gassed for 30 sec. with a mixture of 95% O2-5% CO2 prior to and after decapsulation. Slices of renal cortex (approximately 0.3 mm thick) were prepared using a Stadie-Riggs microtome (A. Thomas Co.). Each cortical slice was further divided into several similarly-sized portions (according to the number of treatments) and then randomly assigned to separate incubation vessels containing 2.5 ml of Robinson's buffer at 0°C. This procedure was repeated using slices from other cortical areas until each vessel contained 50±30 mg of cortical tissue (wet weight). The random distribution of the sliced tissue insured that all incubation beakers contained relatively
homogenous cell populations from each cortical area. One vessel from each group was utilized as a common, non-treated control. The renal cortical tissue was then preincubated for 15 min at 37°C in a shaking Dubnoff Metabolic Incubator (Precision Scientific Co.) in an atmosphere saturated with 95% O₂ - 5% CO₂. The preincubated slices were subsequently transferred to new incubation vessels containing 2.5 ml of fresh Robinson's buffer and incubated for 60 min under 95% O₂ - 5% CO₂ at 37°C.

Groups of beakers having a common, unstimulated control sample, were treated with either prostaglandin E₂ (PGE₂; 10⁻⁵ M) or prostaglandin F₂-alpha (PGF₂-alpha; 10⁻⁵ M) added separately or together with the beta-adrenergic receptor blocker propranolol (10⁻⁴ M), or the alpha-adrenergic receptor blocker phentolamine (10⁻⁴ M) to the renal cortical slice preparation. The prostaglandin synthetase inhibitor, indomethacin (10⁻⁴ M), as well as propranolol and phentolamine were also added alone to the kidney slice system.

Indomethacin, PGE₂ and PGF₂-alpha solutions were prepared in absolute ethanol to the desired concentrations. Propranolol (Sigma) was dissolves in 0.1% ascorbic acid, whereas phentolamine (CIBA) solutions were made in sterile water. The
alpha- and beta-receptor blocking agents as well as indomethacin were added to the tissue preparation before both the pre-incubation and incubation periods. In turn, the prostaglandins were added before the 60 min incubation period only.

Following incubation, the supernatant medium was collected and stored at -20°C before being measured for renin concentration by radioimmunoassay of angiotensin I (200). The incubated tissue used for cyclic AMP content determination was immediately frozen on dry ice, homogenized in 3% trichloracetic acid, and stored at -20°C, until assayed by a modification of the competitive protein-binding assay of Gilman (201).

Extraction and measurement of tissue cyclic AMP were accomplished by thawing the previously frozen tissue homogenates in an ice-cold water bath followed by centrifugation at 4000 rpm for 15 min at 4°C. The supernatant was then transferred to conical centrifuge tubes while the precipitated protein was discarded. The samples were subsequently washed four times with 2.0 ml each of water-saturated ether, and the ether phase discarded. After the final wash, the cyclic AMP-containing water phase was decanted into glass vials placed on dry ice for rapid freezing. The frozen
samples were then lyophilized and the freeze-dried residue was stored at -20°C prior to the measurement of cyclic AMP content. The values were expressed as picomoles of cyclic-AMP per mg of wet tissue.

Renin concentration in the supernatant samples was indirectly measured by determining the rate of angiotensin I generation following exposure of endogenous renin present in the collected medium, to exogenous renin substrate (angiotensinogen) obtained from 6 hr nephrectomized dog plasma, during a two-hour incubation period at 37°C. Angiotensinase-and converting enzyme inhibitors were added to the mixture to prevent conversion of the generated angiotensin I to angiotensin II. Briefly, the supernatant samples were allowed to thaw at 4°C, vortexed for 10 sec and 0.025 ml aliquots were transferred to test tubes at 4°C. Aliquots of 0.4 ml nephrectomized dog plasma (pH=7.56), previously treated with the angiotensinase-and converting enzyme inhibitor phenyl methyl sulfonyl fluoride (PMSF:Sigma) and 2 drops of saturated NaCl, were then added to each test tube and vortexed. The resulting mixture was incubated for 2 hr at 37°C, diluted 3:1 with acidified distilled water, vortexed, and then placed in a boiling water bath for 3 min to terminate the reaction. The samples
were then allowed to cool and then stored at \(-20^\circ\text{C}\) until assayed for angiotensin I by radioimmunoassay. The results were expressed as nanograms of angiotensin I per mg of wet tissue per hr.

Statistical analysis of the data was performed by modified Student's paired t-tests (202) using a programmable desktop calculator (Hewlett-Packard) at Argonne National Laboratories (Argonne, Il.).
RESULTS

The effect of PGE$_2$ (10$^{-5}$ M) and PGF$_2$-alpha (10$^{-5}$ M) on renin release and cyclic AMP content in renal cortical slices from sodium deficient rats, is shown in figure 1. At the dose used, both prostaglandins increased renin secretion by about 2 ng/mg/hr (in 5 out of 9 observations for PGE$_2$ and in 6 out of 10 cases for PGF$_2$-alpha) during a one-hr incubation period, although the increase was not statistically significant. In contrast, tissue cyclic AMP in response to administration of either PGE$_2$ or PGF$_2$-alpha was markedly elevated (p < 0.01) in relation to unstimulated, control samples (significant increases in 11 out of 12 instances for PGE$_2$ and in 10 out of 12 cases for PGF$_2$-alpha).

Administration of the beta-adrenoreceptor blocker, propranolol (10$^{-4}$ M), either alone or together with PGE$_2$ did not alter renin release (in 6 out of 10 instances renin release was increased by PGE$_2$ plus propranolol; in 11 out of 12 cases tissue c-AMP was increased by PGE$_2$ plus propranolol) and did not prevent the stimulatory effect of PGE$_2$ alone on the cyclic AMP content of the renal tissue (Figure 2). Similar results
(in 5 out of 10 cases renin release was increased by PGE$_2$ plus phentolamine; in 11 out of 12 cases tissue CAMP content by PGE$_2$ plus phentolamine) were obtained when the alpha-adrenoreceptor blocker, phentolamine ($10^{-4}$ M), was added to the renal cortical preparation either alone or in conjunction with PGE$_2$ (Figure 3).

Changes in renin release and tissue cyclic AMP content in response to administration of $10^{-5}$ M PGF$_2$-alpha, either alone or together with $10^{-4}$ M propranolol or $10^{-4}$ M phentolamine, are shown in figures 4 and 5, respectively. As seen previously with PGE$_2$, beta- or alpha-adrenergic receptor blockade was ineffective in altering renin secretion (renin release was increased in 6 out of 10 cases by PGF$_2$-alpha plus propranolol and in 6 out of 10 cases of PGF$_2$-alpha plus phentolamine) or in preventing the significant stimulatory effect of PGF$_2$-alpha on tissue cyclic AMP content. (Tissue c-AMP content was increased in 11 out of 12 cases by both PGF$_2$-alpha plus propranolol and PGF$_2$-alpha plus phentolamine.)

To evaluate the possibility that endogenous prostaglandins participate in the regulation of resting (basal) renin release, the prostaglandin synthetase inhibitor, indomethacin ($10^{-4}$ M), was added alone to the kidney slice system during a one-hr incubation period (Figure 6). In the presence of this
agent, both renin release and tissue cyclic AMP content remained unaltered when compared to unstimulated control samples. (Renin release was increased in 1 out of 5 instances and c-AMP content increased in 2 out of 6 cases in response to indomethacin.)
Figure 1. Effect of $10^{-5}$ M prostaglandin E$_2$ (PGE$_2$) and $10^{-5}$ prostaglandin F$_2$-alpha (PGF$_2$-alpha) added separately, on renin release and tissue cyclic AMP content in renal cortical slices from sodium deficient rats. The data represent the mean renin release change $\pm$ SE and the mean tissue cyclic AMP content change $\pm$ SE. The number of observations (n) and the statistical significance of the observations are indicated. The mean control (nontreated) rate of renin release was 6.39 $\pm$ 1.29 ng/mg/hr and the mean control tissue cyclic AMP content was 0.34 $\pm$ 0.04 pmol/mg wet tissue. Incubation time was 60 min.
**Change in Renin Release**

- **Significantly Different From Control (p<0.01)**

**Change in c-AMP**

- **n=9**
- **n=12**

- **PGE$_2$ (10$^{-5}$ M)**
- **PGF$_2$-alpha (10$^{-5}$ M)**

<table>
<thead>
<tr>
<th>CHANGE IN RENIN RELEASE (ng/mg/hr)</th>
<th>CHANGE IN c-AMP (pmol/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>3.5</td>
<td>3.5</td>
</tr>
<tr>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>4.5</td>
<td>4.5</td>
</tr>
</tbody>
</table>

**TREATMENT**

- **CONTROL**

**n=9**

**n=10**

**n=12**
Figure 2. Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$ M prostaglandin E$_2$ (PGE$_2$) added alone or together with $10^{-4}$ M propranolol (PRO) to renal cortical slices from sodium deficient rats. The data represent the mean change in renin release ± SE and the mean tissue cyclic AMP content change ± SE. The number (n) of observations and the statistical significance of the observations are indicated. The mean control (nontreated) rate of renin release for PGE$_2$ added alone or together with PRO was $6.30 \pm 1.29$ ng/mg/hr and it was $6.42 \pm 1.65$ ng/mg/hr for PRO added alone. Corresponding values for tissue cyclic AMP content were $0.34 \pm 0.04$ and $0.39 \pm 0.08$ pmol/mg wet tissue, respectively. Incubation time was 60 min.
The diagram shows the change in renin release (ng/mg/hr) and cAMP (Pmol/mg) with different treatments.

- **PGE\(_2\) (10\(^{-5}\) M)**: 
  - Change in renin release: n=9
  - Change in cAMP: n=12

- **PGE\(_2\) (10\(^{-5}\) M) + Propranolol (10\(^{-4}\) M)**: 
  - Change in renin release: n=10
  - Change in cAMP: n=12

- **Propranolol (10\(^{-4}\) M)**: 
  - Change in renin release: n=5
  - Change in cAMP: n=6

**Significance**: **\(\*\*\) significantly different from control (\(P < .01\))**

In the figure, the bars represent the change in renin release and cAMP for each treatment condition. The error bars indicate the variability in the measurements.
Figure 3. Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$ M prostaglandin $E_2$ (PGE$_2$) added alone or together with $10^{-4}$ M phentolamine (PHEN) to renal cortical slices from sodium deficient rats. The data represent the mean change in renin release ± SE and the mean tissue cyclic AMP content change ± SE. The number (n) of observations and the statistical significance of the observations are indicated. The mean control (nontreated) rate of renin release for PGE$_2$ added alone or together with PHEN was 6.30 ± 1.29 ng/mg/hr and it was 6.42 ± 1.65 ng/mg/hr for PHEN added alone. Corresponding values for tissue cyclic AMP content were 0.34 ± 0.04 and 0.39 ± 0.08 pmol/mg wet tissue, respectively. Incubation time was 60 min.
CHAttGE IN RENIN
RE1..EASE

*Significantly Different From Control (p<0.01)

CHANGE IN RENIN RELEASE
(ng/mg/hr)

CHANGE IN c-AMP

# # Significantly Different From Control (p<0.01)

PGE₂ (10⁻⁵M)

PGE₂ (10⁻⁵M) + PHENTOLAMINE (10⁻⁴M)

PHENTOLAMINE (10⁻⁴M)

TREATMENT

CONTROL

CHANGE IN c-AMP
(pmol/mg)
Figure 4. Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$ M prostaglandin F$_2$-alpha (PGF$_2$-alpha) added alone or together with $10^{-4}$ M propranolol (PRO) to renal cortical slices from sodium deficient rats. The data represent the mean change in renin release ± SE and the mean tissue cyclic AMP content change ± SE. The number (n) of observations and the statistical significance of the observations are indicated. The mean control (non-treated) rate of renin release for PGF$_2$-alpha added alone or together with PRO was $6.30 \pm 1.29$ ng/mg/hr and it was $6.42 \pm 1.65$ ng/mg/hr for PRO added alone. Corresponding values for tissue cyclic AMP content were $0.34 \pm 0.04$ and $0.39 \pm 0.08$ pmol/mg wet tissue, respectively. Incubation time was 60 min.
Change in Renin Release

**Significantly Different From Control (p<0.01)**

- Change in c-AMP

CHANGE IN RENIN RELEASE (ng/mg/hr)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n=10</th>
<th>n=12</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGF₂ alpha (10⁻⁵ M)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGF₂ alpha (10⁻⁵ M) + Phentolamine (10⁻⁴ M)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phentolamine (10⁻⁴ M)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTROL

1.5

CHANGE IN C-AMP (pmol/mg)

-1.8

1.2

0.9

0.6

0.3
Figure 5. Changes in renin release and tissue cyclic AMP content in response to $10^{-5}$ M prostaglandin F$_2$-alpha (PGF$_2$-alpha) added alone or together with $10^{-4}$ M phentolamine (PHEN) to renal cortical slices from sodium deficient rats. The data represent the mean change in renin release ± SE and the mean tissue cyclic AMP content change ± SE. The number (n) of observations and the statistical significance of the observations are indicated. The mean control (nontreated) rate of renin release for PGF$_2$-alpha added alone or together with PHEN was $6.30 \pm 1.29$ ng/mg/hr and $6.42 \pm 1.65$ ng/mg/hr for PHEN added alone. Corresponding values for tissue cyclic AMP content were $0.34 \pm 0.04$ and $0.39 \pm 0.08$ pmol/mg wet tissue, respectively. Incubation time was 60 min.
= CHANGE IN RENIN RELEASE

**= Significantly Different From Control (p < .01)

= CHANGE IN c-AMP

CHANGE IN RENIN RELEASE (ng/mg/hr)

CHANGE IN cAMP (pmol/mg)

CONTROL

PGE$_2$-alpha (10$^{-5}$M)

PGE$_2$-alpha (10$^{-5}$M)

PROPRANOLOL (10$^{-4}$ M)

+ PROPRANOLOL (10$^{-4}$ M)

TREATMENT

n=10  n=12  n=10  n=12  n=5

n=6
Figure 6. The effect of $10^{-4}$ M indomethacin (I) on resting renin release and tissue cyclic AMP content in renal cortical slices from sodium deficient rats. The data represent the mean renin release ± SE and the mean tissue cyclic AMP content ± SE of I-treated slice tissue (I) in relation to unstimulated controls (c). The number (n) of observations are indicated. Incubation time was 60 min.
INDOMETHACIN (I) $10^{-4}$ M

RENIN RELEASE (ng/mg/hr) 4.8 3.6 2.4 1.2

RENIN release

n=6

n=5

cAMP (Pmol/mg)

1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2

C I

C I

C I
DISCUSSION

The in vitro renal cortical slice preparation has been demonstrated to be a metabolically-viable system, as judged by the linearity of renin release and tissue oxygen consumption observed with time of incubation (1,3,203-207). Utilization of this type of preparation, which is devoid of hemodynamic, humoral and other factors known to affect renin secretion in the live animal, has allowed an effective evaluation of the direct effect of a number of isolated agents on renin release (1-4,87,96,98,101,117,208-211), including those exerted by prostaglandins (9,10,13,14).

In the present study, the inability of both PGE$_2$ and PGF$_2$-alpha to significantly stimulate renin release in vitro is consistent with previous reports which suggest that administration of these agents either does not affect renin release (11,12,15) or it only exerts a mild stimulatory effect (10). Alternatively, some studies (7,179,181,182) have provided data supporting the concept that PGE$_2$ has the ability to significantly stimulate renin release, whereas others (9,13,14) have reported that PGF$_2$-alpha significantly depresses renin secretion.
One possible explanation for the conflicting nature of the data generated in these various studies, may be related to the nature of the vehicle in which the prostaglandins are routinely prepared. Whorton et al. (10) have shown that when ethanol is used as the solvent, concentrations of this agent as low as ul/5 ml of incubation medium diminish the stimulatory effect of PGE$_1$ on renin release by 33%, and that administration of similarly-prepared PGF$_2$-alpha actually inhibits renin secretion. Conversely, the same investigators have shown that PGF$_2$-alpha significantly stimulates renin release only when dissolved in albumin-containing physiological buffer. Although there are no corresponding data pertaining to PGE$_2$, the fact that absolute ethanol was utilized in the present study as the prostaglandin vehicle, may partially account for the inability of both PGE$_2$ and PGF$_2$-alpha to significantly influence renin release. A likely way by which ethanol may participate in the prevention of the stimulatory effect of these prostaglandins on renin secretion may be through its well-known dehydrating properties, which would impair the metabolic viability of the renal cortical cells. However, our observation that the cyclic AMP content of our renal cortical tissue was significantly increased, rather than decreased, by the addition
of PGE₂ and PGF₂-alpha in this study makes a detrimental effect of ethanol a less likely possibility.

To our knowledge, renin release and tissue cyclic AMP content responses to prostaglandin administration have not been simultaneously evaluated in previous studies. The consistently significant increases in tissue cyclic AMP content caused by both PGE₂ and PGF₂-alpha in this study, agree with previous observations showing a marked stimulation of renal adenylate cyclase systems by these agents (187-188). Whether or not the increase in cyclic AMP seen in those studies was coupled with corresponding changes in renin release can not be determined, since the two parameters were not measured simultaneously.

Clearly, however, our data indicate that at least at the dose used in this study for both prostaglandins, their effects on renin release and tissue cyclic AMP content were independent of each other. The different effects on these two parameters caused by PGE₂ and PGF₂-alpha administration, contrast with data related to the stimulatory effect exerted by catecholamines on renin secretion. In these studies (1-4,35,36), norepinephrine and dopamine significantly stimulated both renin release and tissue cyclic AMP content in rat renal cortical tissue, suggesting that the renal receptor mechanism
involved in these stimulatory responses utilizes cyclic AMP as a mediator. Furthermore, the same investigators have shown that the stimulatory effect of these catecholamines on both parameters, was effectively blocked by the beta-adrenoreceptor antagonist, propranolol, suggesting that the type of receptor mechanism mediating these responses is of the beta-type.

Thus, the marked stimulatory effect of PGE$_2$ and PGF$_2$-alpha on tissue cyclic AMP content seen in the present study, may reflect a selective, rather than generalized, stimulation of renal-adenylate cyclase complexes different from those located on the membrane of the JG cells. The observation that propranolol administration did not alter the stimulatory effect caused by both prostaglandins on tissue cyclic AMP content, is consistent with this view.

A number of studies (1,35,36,115,117,212) have also shown that renal alpha-adrenergic receptor stimulation markedly depresses renin release and tissue cyclic AMP content, and that this inhibitory effect on both parameters is effectively converted to stimulation by administration of alpha-adreno-receptor blocking agents. The present results indicate that alpha-adrenergic receptors do not participate in the action of PGE$_2$ or PGF$_2$-alpha on either renin release or tissue cyclic AMP content, since alpha adrenoreceptor blockade by phentolamine
did not alter the changes seen in both parameters in response to administration of either prostaglandin. Thus, it appears that neither beta-adrenergic nor alpha-adrenergic receptor mechanisms, mediate the stimulatory effect of PGE$_2$ and PGF$_2$ on the renal cyclic AMP content seen in this study. Also, it is clear that at the dose used in this investigation, neither prostaglandin was capable of significantly altering resting renin release. However, before a definite conclusion regarding the possibility that prostaglandins may influence renin release can be reached, additional doses of these agents must be examine, and alternative prostaglandins such as prostacyclin (PGI$_2$) must be evaluated alone and in conjunction with blocking agents. Furthermore, immunohistochemical studies designed to isolate the actual site of PG-stimulated cyclic AMP content would be of great value in this regard.

**In vitro** studies utilizing renal cortical tissue of rabbits (13,14) have shown that indomethacin, a known prostaglandin synthetase inhibitor, significantly suppresses resting renin release, an observation which suggests that endogenous renal prostaglandins participate in the minute-to-minute regulation of renin secretion in this species. Similarly, Romero
et al. (25) have demonstrated in live dogs that indomethacin is a potent inhibitor of resting renin release. Using the same concentration of indomethacin, \(10^{-4}\)M, as these workers, we observed a mean decrease in resting renin release after 60 min of incubation, although this decrease was not statistically significant. Thus, the present in vitro data do not currently support the concept that resting renin release is under partial modulation by intrarenal prostaglandins. Alternatively, our results in the rat may be indicative of species differences or of differences in dietary sodium intake, since previous studies employed animals maintained on commercial, sodium replete diets. The inability of indomethacin to influence resting renin release in this study, was also apparent in regard to the cyclic AMP content of the renal cortical tissue. This observation further supports our view that in vitro renin secretion in the rat is not regulated to any significant extent by endogenous renal prostaglandins, since their activity should have been reflected in an increased adenylate cyclase stimulation mimicking that observed in this study upon administration of exogenous \(\text{PGE}_2\) and \(\text{PGF}_2\)-alpha. It is clear that further studies, designed to determine whether or nor the marked stimulatory effect exerted by these prostaglandins on
renal adenylate cyclase complexes can be altered by simultaneous indomethacin administration, are required before these questions can be effectively answered.
REFERENCES


90. Winer, N., D. S. Chokshi and M. C. Valkenhorst, 1971. Effects of cyclic AMP, sympathomimetic amines and


E₂-induced hypertension in conscious dogs. *Am. J.

intrarenal prostaglandin E₂ infusion in the dog. In: 
Advances in Prostaglandin and Thromboxane Research, 
Vol. 7. B. Samuelsson, P. W. Ramwell and R. Paoletti 

litch, 1977. Evidence for prostacyclin production in 

186. Gerber, J. G., E. Ellis, J. Hollifield and A. S. Nies, 
1979. Effect of prostaglandin endoperoxide analogues 
on canine renal function, hemodynamics and renin re­

luation of adenylate cyclase in isolated rat glomeruli 

glandins on rat renal adenylate cyclase-cyclic AMP sys­

189. Birnbaumer, L. and P. C. Yang, 1974. Studies on receptor-
mediated activation of adenyl cyclases III. Regulation by 
purine nucleotides of the activation of adenyl cyclases 
from target organs for prostaglandins, lutenizing hormone, 
neurohypophyseal hormones and catecholamines. Tissue and 
hormone-dependent reactions. *J. Biol. Chem.*, 249: 7867-
7873.

prostaglandin, E₂ on the adenyl cyclase-cyclic AMP system 
421: 203-209.

191. Taher, S., P. Cadnapaphornchai, N. Bondar, R. Faba, K. 
Shaw and F. D. McDonald, 1979. Effect of prostaglandin 
inhibition on cyclic AMP mediated renal vasodilation 


The thesis submitted by Brett C. Sheppard has been read and approved by the following committee:

Dr. Genard A. Lopez  
Assistant Professor  
Biology, Loyola  

Dr. John J. Peluso  
Assistant Professor  
Biology, Loyola  

Dr. Charles C. C. Morchoe  
Professor and Chairman  
Dept. of Anatomy  
Loyola Stritch School of Medicine  

The final copies have been examined by the director of the thesis and the signature which appears below verifies the fact that any necessary changes have been incorporated and that the thesis is now given final approval by the Committee with reference to content and form.

The thesis is therefore accepted in partial fulfillment of the requirements for the degree of Master of Science.

December 5, 1980  
Date  

Gumar A. Lopez  
Director's Signature